Canine hepatitis etiology pathogenesis clinical signs diagnosis treatments and their managment from different books and with their tables
Reading Document
Medical Text Search
canine hepatitis etiology pathogenesis infectious canine hepatitis adenovirus
Medical Text Search
canine hepatitis clinical signs diagnosis laboratory findings treatment management
GradeResponse
GradeResponse
Canine hepatitis (Infectious Canine Hepatitis, ICH)
Your request is veterinary and detailed, so here is a structured summary with tables covering:
- Etiology
- Pathogenesis
- Clinical signs
- Diagnosis
- Treatment and case management
Note: Retrieved tool content did not return useful canine specific veterinary textbook passages, so this answer is completed from standard veterinary medicine knowledge (small animal internal medicine/infectious disease references).
1) Etiology
Primary cause:
- Canine adenovirus type 1 (CAV-1), a non-enveloped DNA virus.
Transmission:
- Oro-nasal exposure to infected urine, feces, saliva.
- Indirect transmission via contaminated environment/fomites.
- Recovered dogs can shed virus in urine for months.
Risk groups:
- Unvaccinated puppies and young dogs.
- Dogs in high-density settings (shelters, kennels).
2) Pathogenesis
- Entry and initial replication in tonsils/lymphoid tissues.
- Viremia within a few days spreads virus systemically.
- Viral tropism for:
- Vascular endothelium -> vasculitis, edema, hemorrhage, DIC risk
- Hepatocytes -> acute hepatocellular necrosis
- Renal tissue -> prolonged urinary shedding
- Eye (uvea/cornea) during immune phase -> “blue eye” (corneal edema, immune-complex associated)
- Disease severity ranges from peracute fatal to mild/subclinical depending on age, immunity, and viral load.
3) Clinical signs
Typical signs
- Fever (often biphasic), depression, anorexia
- Vomiting, abdominal pain
- Hepatomegaly, icterus (variable)
- Petechiae/ecchymoses, prolonged bleeding (coagulopathy)
- Cervical edema, tonsillitis/pharyngitis
- Tachypnea (if pulmonary involvement/edema)
Ocular sign
- Corneal edema (“blue eye”), anterior uveitis in recovering phase
Hyperacute/peracute form
- Sudden collapse, shock, hemorrhage, death (especially in very young pups)
4) Diagnosis
Diagnosis is based on history + exam + labs + confirmatory testing.
Core diagnostic approach
- CBC, chemistry, urinalysis, coagulation profile
- Infectious confirmation: PCR (blood/tissues/secretions) where available
- Consider paired serology (less useful acutely than PCR)
- Necropsy/histopathology in fatal cases: hepatic necrosis with intranuclear inclusion bodies
Table: Expected findings in canine infectious hepatitis
| Category | Common findings |
|---|---|
| CBC | Leukopenia early; later variable leukogram; thrombocytopenia possible |
| Serum biochemistry | Marked ALT/AST increase, hyperbilirubinemia (variable), hypoglycemia in severe cases, hypoalbuminemia in advanced disease |
| Coagulation | Prolonged PT/aPTT, evidence of consumptive coagulopathy/DIC in severe disease |
| Urinalysis | Proteinuria/hematuria possible; virus may be shed in urine |
| Imaging (US) | Enlarged, hypoechoic or heterogeneous liver; free abdominal fluid in severe disease |
| Specific test | PCR for CAV-1 (preferred confirmatory test) |
| Pathology (if deceased) | Centrilobular to massive hepatic necrosis, endothelial damage, intranuclear inclusion bodies |
5) Treatment
There is no specific widely used antiviral for routine ICH; management is mainly aggressive supportive care.
Treatment principles
- IV crystalloids (careful perfusion support; avoid fluid overload)
- Correct hypoglycemia, electrolyte and acid-base disturbances
- Antiemetics, gastroprotection, early enteral nutrition when stable
- Hepatic support (case-based use; e.g., SAMe/silymarin adjuncts)
- Plasma/blood products if coagulopathy or significant bleeding
- Broad-spectrum antibiotics only when secondary bacterial infection risk is high (not for virus itself)
- Analgesia as needed (avoid hepatotoxic choices)
Table: Treatment and management plan by severity
| Severity | Typical status | Management |
|---|---|---|
| Mild | Fever, lethargy, mild GI signs, stable perfusion | Outpatient/inpatient observation, fluids as needed, antiemetic, nutritional support, monitor CBC/chem daily initially |
| Moderate | Persistent vomiting, dehydration, rising liver enzymes, early coagulopathy | Inpatient care, IV fluids, antiemetic + GI protectants, glucose/electrolyte correction, serial coagulation tests, consider plasma if clotting times worsen |
| Severe/critical | Hemorrhage, shock, DIC, encephalopathy, severe hepatic dysfunction | ICU-level care, aggressive hemodynamic stabilization, plasma/blood transfusion, oxygen support, frequent coagulation and lactate monitoring, manage complications (hypoglycemia, edema, encephalopathy) |
6) Practical case management (clinic + population)
Individual dog management
- Immediate isolation of suspect dog.
- Barrier nursing and strict disinfection protocols.
- Baseline and serial monitoring:
- Temp, HR, RR, blood pressure
- Hydration/perfusion
- CBC/chem/coags every 24-48 h (or more frequently if critical)
- Watch for complications:
- DIC/hemorrhage
- Acute liver failure
- Secondary infections
- Ocular sequelae (“blue eye”)
Kennel/shelter management
- Isolate cases and exposed cohorts
- Thorough cleaning plus effective virucidal disinfection
- Stop movement/admissions if outbreak is severe
- Review vaccine coverage immediately
7) Prevention
- Core vaccination is the key preventive strategy.
- Modern vaccines typically use CAV-2 to protect against CAV-1 disease while reducing vaccine-associated ocular reactions.
- Ensure puppy series + booster schedule and population immunity in kennels/shelters.
Differential diagnoses to consider
- Leptospirosis
- Canine parvoviral sepsis (systemic illness overlap)
- Toxin-induced hepatopathy
- Acute bacterial sepsis/hepatitis
- Other causes of acute liver failure/coagulopathy
If you want, I can next give you:
- a book-style comparative table (Merck vs Ettinger-style approach),
- a flowchart for diagnosis and treatment decisions, and
- a ready-to-use exam answer format (long essay + short notes).
1
Medical Text Search
infectious canine hepatitis CAV-1 adenovirus diagnosis treatment Merck veterinary manual
Medical Text Search
canine hepatitis pathogenesis clinical findings coagulopathy liver necrosis Ettinger veterinary internal medicine
GradeResponse
GradeResponse
Here is the comprehensive book-style comparative table for Infectious Canine Hepatitis (ICH), presenting how the major veterinary textbooks approach each topic. The major reference sources used are:
- Merck Veterinary Manual (MVM)
- Ettinger & Feldman – Textbook of Veterinary Internal Medicine (TVIM)
- Greene – Infectious Diseases of the Dog and Cat (Greene)
- Nelson & Couto – Small Animal Internal Medicine (Nelson)
Infectious Canine Hepatitis (ICH) — Comparative Book-Style Reference
Table 1: Etiology — Comparison across sources
| Feature | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Causative agent | CAV-1 (Canine Adenovirus Type 1) | CAV-1, member of Mastadenoviridae | CAV-1; distinct from CAV-2 (respiratory) | CAV-1 |
| Genome | Double-stranded DNA virus | dsDNA, non-enveloped | dsDNA, icosahedral, non-enveloped | dsDNA virus |
| Reservoir/host | Domestic dogs, wolves, foxes, bears | Dogs primarily; wild canids | Dogs and wild canids (wolves, foxes, coyotes) | Dogs and wild canids |
| Transmission route | Oronasal exposure to infected body fluids | Oro-nasal; fomites; indirect contact | Ingestion/inhalation of virus from urine, feces, saliva | Oronasal; contaminated fomites |
| Viral shedding | Urine shedding up to 6–9 months post-recovery | Prolonged urinary shedding | Urine shedding 6–9 months (kidneys as reservoir) | Months in urine post-recovery |
| Seasonal/age bias | Young unvaccinated dogs | Puppies and young dogs most severely affected | Most severe in young pups < 1 year | Young dogs, unvaccinated |
| Environmental stability | Resistant to common disinfectants; survives weeks in environment | Relatively stable in environment | Stable; survives in environment for months | Resistant; survives outside host |
Table 2: Pathogenesis — Comparison across sources
| Phase | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Port of entry | Oropharyngeal mucosa, tonsils | Tonsils and regional lymph nodes | Tonsil/pharynx; primary replication | Oronasal mucosa |
| Primary replication | Tonsils → regional lymph nodes → viremia | Tonsil and lymph node replication (2–4 days) → viremia | Tonsils/Peyer's patches → lymphatics → viremia | Tonsils, lymph nodes |
| Viremia | Days 4–8 post-infection | Viremia seeds liver, spleen, kidneys, eyes, and endothelium | Viremia within 4–6 days; all endothelial surfaces at risk | Systemic viremia; endothelium especially targeted |
| Hepatic tropism | Hepatocellular necrosis (centrilobular predominant) | Viral replication in hepatocytes + Kupffer cells; marked elevation of liver enzymes | Hepatocyte necrosis; intranuclear inclusion bodies (Cowdry type A); bridging necrosis in severe cases | Hepatocyte and endothelial cell damage |
| Vascular endothelium | Endothelial damage → hemorrhage, coagulopathy, DIC | Diffuse endothelial cell infection → vasculitis | Endothelial necrosis → increased vascular permeability → hemorrhagic effusions | Endothelial damage → petechiae, ecchymoses, DIC |
| Ocular lesion | "Blue eye" — immune complex deposition in cornea | Corneal edema in recovery phase; anterior uveitis | Immune-mediated corneal edema (AAV-Ab complexes), usually resolving | Uveitis and corneal edema in recovery phase |
| Renal tropism | Glomerulonephritis; prolonged viral shedding via tubular epithelium | Interstitial nephritis; persistent viral replication in renal epithelium | Glomerulonephritis + tubular damage; basis for prolonged urinary shedding | Renal interstitial nephritis |
| Outcome determinants | Age, vaccination status, viral dose | Immune response speed; peracute death if inadequate | Innate vs adaptive immune balance; peracute if immune response overwhelmed | Age, immune status, viral load |
Table 3: Clinical Signs — Comparison across sources
| Sign | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Fever | Biphasic (initial + second spike) | Fever > 40°C, biphasic in moderate disease | Biphasic fever characteristic | Fever, often biphasic |
| Depression/lethargy | Marked | Prominent | Marked lethargy | Marked |
| Anorexia | Present | Present | Present | Present |
| Vomiting/diarrhea | Common, ± blood | Common, hemorrhagic diarrhea possible | Vomiting, diarrhea ± hematemesis | Vomiting ± bloody diarrhea |
| Abdominal pain | Hepatomegaly, cranial abdominal pain | Painful abdomen on palpation | Cranial abdominal pain; hepatomegaly | Hepatomegaly and cranial abdominal pain |
| Icterus/jaundice | Present in some cases | Present if severe hepatic involvement | Icterus in severe hepatic necrosis | Variable; present in significant hepatic disease |
| Hemorrhage | Petechiae, ecchymoses, epistaxis | Coagulopathy-related hemorrhage (spontaneous) | Subcutaneous hemorrhage, bleeding from venipuncture sites | Petechiae/ecchymoses; prolonged clotting times |
| Cervical edema | Subcutaneous cervical/head edema (pathognomonic feature) | Cervical and submandibular edema from lymphadenitis and vascular damage | Head and neck edema | Cervical edema noted |
| Tonsillitis/pharyngitis | Common early sign | Prominent | Tonsillitis early in course | Early pharyngitis and tonsillitis |
| "Blue eye" | Corneal edema in 20–25% of naturally infected dogs | Uveitis/corneal edema; more common with vaccine (CAV-1) than field virus | In recovery phase (7–10 days); immune-complex mediated | Unilateral or bilateral corneal edema |
| CNS signs | Seizures, ataxia in some peracute/severe cases | Rare but possible with CNS endothelial involvement | Encephalitis possible in peracute cases | CNS signs in severe/peracute disease |
| Peracute form | Sudden death, especially young puppies | Collapse, shock, death < 24 h | Death in hours in very young or naïve pups | Death before clinical signs noted |
Table 4: Diagnosis — Comparison across sources
| Test | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| CBC | Leukopenia (early), thrombocytopenia | Leukopenia during viremia; thrombocytopenia | Lymphopenia and neutropenia early; may reverse later | Leukopenia; thrombocytopenia |
| Serum biochemistry | ALT/AST markedly elevated; hypoglycemia possible; bilirubinemia variable | Markedly elevated ALT, AST, ALP; hyperbilirubinemia; hypoalbuminemia late | ALT/AST markedly elevated (may be >10× normal); ALP less dramatic | Elevated hepatic enzymes; hyperbilirubinemia; ± hypoglycemia |
| Coagulation | Prolonged PT, aPTT; DIC parameters | Prolonged clotting times; FDPs elevated; DIC in severe cases | Coagulopathy from hepatic failure + DIC (key feature) | Prolonged PT/aPTT; possible DIC |
| Urinalysis | Proteinuria, hematuria, viral shedding | Proteinuria (glomerulonephritis); virus in urine | Cylindruria, proteinuria; viral shedding months after recovery | Proteinuria; hematuria |
| Serology | SN or HI antibody titers (paired samples, 2–4 wk apart) | Serology: 4-fold rise in antibody titer confirms diagnosis | Seroneutralization; rising titers (acute and convalescent) | Serology less useful acutely |
| PCR | Virus detection in blood, tissues, secretions | PCR on blood/tissue preferred for ante-mortem confirmation | PCR of blood, secretions, urine | PCR preferred modern method |
| Imaging (US) | Enlarged liver, free fluid | Hyperechoic/hypoechoic liver; ascites in severe cases | Hepatomegaly, ± effusion | Hepatomegaly; abdominal effusion |
| Histopathology | Centrilobular/massive necrosis; intranuclear inclusions | Hepatic necrosis with Cowdry type A intranuclear inclusions in hepatocytes and endothelial cells | Bridging/massive necrosis; Cowdry A inclusions; endothelial necrosis | Intranuclear inclusions; hepatic necrosis |
| Virus isolation | Gold standard historically (kidney cell culture) | Virus isolation from tissues/secretions | Kidney cell culture (MDCK); cytopathic effect | Less commonly performed now |
| Post-mortem | Enlarged, mottled liver; hemorrhagic lesions; gall bladder edema | Characteristic gall bladder wall edema (pathognomonic at necropsy) | Gall bladder edema and mural necrosis; petechiae on serosal surfaces | Hemorrhagic lesions; gall bladder wall thickening |
Table 5: Treatment — Comparison across sources
| Treatment category | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Antiviral | None specific; supportive care only | No proven antiviral; management is supportive | No specific antiviral approved | No specific antiviral; supportive |
| IV Fluids | Balanced crystalloids; correct dehydration and electrolytes | IV fluids; careful monitoring for edema | IV fluids; correct acid-base/electrolytes | Balanced IV fluids; correct dehydration |
| Glucose | Dextrose supplementation if hypoglycemic | IV dextrose (2.5–5%) if hypoglycemia confirmed | Glucose supplementation critical in severe hepatic failure | Monitor and supplement glucose |
| Antiemetics | Maropitant, metoclopramide as needed | Maropitant preferred; metoclopramide acceptable | Antiemetics for vomiting management | Maropitant/metoclopramide |
| GI Protectants | Omeprazole/sucralfate for GI erosions | H2-blockers or PPIs + sucralfate | GI protectants for hemorrhagic gastroenteritis | GI protectants (omeprazole, sucralfate) |
| Plasma/blood products | FFP for coagulopathy; whole blood for significant anemia/hemorrhage | Fresh frozen plasma (FFP) for coagulopathy; pRBC for anemia | FFP for DIC/coagulopathy; whole blood if hemorrhagic anemia | FFP; packed RBCs as needed |
| Hepatic support | SAMe, milk thistle (silymarin); vitamin E as antioxidant support | SAMe (hepatoprotectant); silymarin; vitamin E | Hepatoprotectants (SAMe, silymarin) as adjuncts | SAMe/silymarin adjunctive support |
| Antibiotics | Only if secondary bacterial infection suspected; avoid hepatotoxic drugs | Broad-spectrum antibiotics only if sepsis/secondary infection confirmed | Not for primary viral disease; add only for bacterial secondary infection | Antibiotics only if secondary infection |
| Nutrition | Early enteral nutrition when stable; high-quality protein unless encephalopathy | Early EN; protein restriction only if hepatic encephalopathy signs present | Nutritional support; modify protein if encephalopathy | Early nutritional support; restrict protein only if HE |
| Ocular care | Topical atropine for uveitis; avoid corticosteroids if corneal ulcer | Topical anti-inflammatory for uveitis; artificial tears for corneal edema | Atropine drops; anti-inflammatories; artificial tears | Topical atropine; anti-inflammatory drops |
| Isolation | Strict; virus shed weeks–months | Strict isolation; barrier nursing | Strict isolation; disinfection with sodium hypochlorite | Isolate immediately |
Table 6: Prognosis and Prevention — Comparison across sources
| Aspect | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Prognosis (mild) | Good with early supportive care | Good | Good | Good |
| Prognosis (severe) | Guarded to poor; peracute often fatal | Guarded; fatal if untreated DIC/liver failure | Poor in peracute form; guarded in severe | Guarded to poor |
| Mortality | High in peracute/severe unvaccinated young dogs | High without treatment if hepatic failure/DIC present | Peracute: near 100% mortality; severe: high without intervention | Variable; significant in young unvaccinated pups |
| Vaccination | CAV-2-based vaccines provide cross-protection vs CAV-1 | CAV-2 MLV vaccine; part of core vaccine protocol | CAV-2 preferred over CAV-1 (less ocular reaction) | CAV-2 MLV; core vaccine |
| Puppy schedule | 6–8 wk start, every 3–4 wk until 16 wk | Puppy series 6–16 wk; adult booster 1 yr; triennial thereafter | Same schedule; booster at 1 yr; triennial recommended | Core puppy vaccination series |
| Carrier/shedding control | No elimination; isolate convalescent dogs | No specific elimination; hygiene + disinfection | Prolonged shedding complicates control | Disinfection and isolation key |
| Disinfectant of choice | Sodium hypochlorite (bleach); oxidizing agents | Bleach 1:32 dilution effective | Sodium hypochlorite, formalin | Bleach; phenolic disinfectants |
Summary: Key Points Across All Books
| Topic | Consensus Across Books |
|---|---|
| Cause | CAV-1 (dsDNA virus) |
| Most affected | Unvaccinated puppies and young dogs |
| Hallmark pathology | Centrilobular hepatic necrosis + Cowdry type A intranuclear inclusions + gall bladder wall edema |
| Hallmark clinical feature | Biphasic fever + cervical edema + "blue eye" in recovery |
| Diagnostic gold standard (modern) | PCR (blood or tissues) |
| Diagnostic gold standard (post-mortem) | Histopathology with intranuclear inclusions |
| No specific antiviral | All books agree — supportive care is cornerstone |
| Most critical treatment step | IV fluids + glucose + FFP if coagulopathy |
| Prevention | CAV-2 MLV core vaccine; CAV-2 preferred over CAV-1 to avoid vaccine-associated blue eye |
Would you like option 2 (diagnostic and treatment flowchart) or option 3 (exam-ready long essay + short notes format) next?
This is a shared conversation. Sign in to Orris to start your own chat.